Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results DOI Creative Commons
Т. V. Beketova, N. О. Levina,

Yu. A. Uskova

et al.

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 465 - 473

Published: Oct. 31, 2024

Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, particular those receiving anti-B cell therapy rituximab (RTX), post-vaccination effect may be insufficient. Since 2022 long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for The aim study is to evaluate effectiveness (TC) COVID-19 its safety RTX treated patients AAV. Materials methods . prospective included 63 AAV RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March June 2023, TC was administered a total dose 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 2024 telephone online survey conducted simultaneously identify confirmed cases adverse reactions. also Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering duration (6 months), were divided into two groups depending on interval after last administration TC: up 6 months inclusive – group 1; more than 2. Results During two-year follow-up period, detected 31.7% median between development 5.5 [2–19] months. 1, which 12 COVID-19, 92% had mild form disease, only one lung damage, there no fatal outcomes. 2, cessation accompanied by damage 89% cases, required hospitalization 78%, patients. Four prolonged course persistence SARS-CoV-2 (pCOVID, persistent COVID). 4 including 3 pCOVID, treatment carried out combined antiviral drug nirmarelvir + ritonavir (Skyvira) combination intravenous human immunoglobulin (IVIG) effect. There statistically significant differences incidence secondary immunodeficiency without it (p=0.868). final stage study, serum level IgG examined 34 70.4 (0.33–1086.1) binding antibody units (BAU), indicates lack neutralizing most patients; statistical their (p=0.685). No reactions directly related use observed. A high TSQM-9 global satisfaction domain noted 71.4 (14.3–100); 72,4% respondents answered “satisfied”– “extremely satisfied” first question (effectiveness domain). Conclusions Pre-exposure using RTM safe allowed reduce avoid deaths during period action. After TC, an increase frequency need observed, pCOVID noted. Skyvira IVIG effective all cases. MAB other rheumatic diseases requires further in-depth study.

Language: Английский

“Inflammatory Pathways in Patients with Post-acute Sequelae of COVID-19 – The Role of the Clinical Immunologist” DOI
Matthew Elliott,

A. O'Connor,

Gailen D. Marshall

et al.

Annals of Allergy Asthma & Immunology, Journal Year: 2024, Volume and Issue: 133(5), P. 507 - 515

Published: Aug. 23, 2024

Language: Английский

Citations

3
Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever DOI Open Access
Der‐Shan Sun,

Te-Sheng Lien,

Hsin‐Hou Chang

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1898 - 1898

Published: Feb. 22, 2025

Virus-induced antibodies represent a dual-edged sword in the immune response to viral infections. While are critical for neutralizing pathogens, some can paradoxically exacerbate disease severity through mechanisms such as antibody-dependent enhancement (ADE), autoantibody, and prolonged inflammation. Long coronavirus (COVID) dengue hemorrhagic fever (DHF) exemplify conditions where pathogenic play pivotal role progression. COVID is associated with persistent dysregulation autoantibody production, leading chronic symptoms tissue damage. In DHF, pre-existing against virus contribute ADE, amplifying replication, activation, vascular permeability. This review explores underlying these antibody responses, highlighting shared pathways of comparing distinct features both conditions. By examining studies, we identify key lessons therapeutic strategies, vaccine design, future research aimed at mitigating severe outcomes

Language: Английский

Citations

0
Overlapping conditions in Long COVID at a multisite academic center DOI Creative Commons
Stephanie L. Grach, Daniel V. Dudenkov,

Beth Pollack

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 25, 2024

Many patients experience persistent symptoms after COVID-19, a syndrome referred to as Long COVID (LC). The goal of this study was identify novel new or worsening comorbidities self-reported in with LC.

Language: Английский

Citations

1
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results DOI Creative Commons
Т. V. Beketova, N. О. Levina,

Yu. A. Uskova

et al.

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 465 - 473

Published: Oct. 31, 2024

Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, particular those receiving anti-B cell therapy rituximab (RTX), post-vaccination effect may be insufficient. Since 2022 long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for The aim study is to evaluate effectiveness (TC) COVID-19 its safety RTX treated patients AAV. Materials methods . prospective included 63 AAV RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March June 2023, TC was administered a total dose 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 2024 telephone online survey conducted simultaneously identify confirmed cases adverse reactions. also Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering duration (6 months), were divided into two groups depending on interval after last administration TC: up 6 months inclusive – group 1; more than 2. Results During two-year follow-up period, detected 31.7% median between development 5.5 [2–19] months. 1, which 12 COVID-19, 92% had mild form disease, only one lung damage, there no fatal outcomes. 2, cessation accompanied by damage 89% cases, required hospitalization 78%, patients. Four prolonged course persistence SARS-CoV-2 (pCOVID, persistent COVID). 4 including 3 pCOVID, treatment carried out combined antiviral drug nirmarelvir + ritonavir (Skyvira) combination intravenous human immunoglobulin (IVIG) effect. There statistically significant differences incidence secondary immunodeficiency without it (p=0.868). final stage study, serum level IgG examined 34 70.4 (0.33–1086.1) binding antibody units (BAU), indicates lack neutralizing most patients; statistical their (p=0.685). No reactions directly related use observed. A high TSQM-9 global satisfaction domain noted 71.4 (14.3–100); 72,4% respondents answered “satisfied”– “extremely satisfied” first question (effectiveness domain). Conclusions Pre-exposure using RTM safe allowed reduce avoid deaths during period action. After TC, an increase frequency need observed, pCOVID noted. Skyvira IVIG effective all cases. MAB other rheumatic diseases requires further in-depth study.

Language: Английский

Citations

0